Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial of arsenic trioxide for relapsed or refractory acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Trisenox (arsenic trioxide)

Snippet

Sponsor: Stanford University | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Status: WITHDRAWN